Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Therefore, 0 reasons for buying shares. The new investors have not substantial reason to buy NEOM shares.
This means that Ya Global have to force Bankruptcy soon.
Real contracts? I still think that we have been fooled. Where is the billionaire who bought shares of NEOM? I think it's all a perfect assembly. IMHO.
She is leading the company to bankruptcy. She has consented that Ya Global causes a death spiral. The lower NEOM shares provoque that Ya Global will further shares to dilute. This means that debt can mean 27MM = 270 billion shares conversion price $0.0001. Thanks Laura. Your NEOM management is exemplary. IMHO.
NEOM Thanks Laura (CEO) for your retail investor help...
NEOM $0.0007 - No comment... Ya Global Dilution Machine...
RLTR time to buy!
RLTR Low float play! Only 200MM shares!
RLTR Low float play! Only 200MM shares!
$ONCS Close in $.25
Clear accumulation! Next step $.30!
ONCS See another chart:
ONCS See another chart:
$ONCS Strong accumulation according CHART!
See last article!!!:
http://www.bolsatrading.eu/2013/04/4-reasons-to-buy-oncosec-medical.html
$ONCS Strong accumulation according CHART!
See last article!!!:
http://www.bolsatrading.eu/2013/04/4-reasons-to-buy-oncosec-medical.html
ONCS $0.25!!!!!!!!!!!!!!
See last article!!!:
http://www.bolsatrading.eu/2013/04/4-reasons-to-buy-oncosec-medical.html
ONCS $0.25!!!!!!!!!!!!!!
See last article!!!:
http://www.bolsatrading.eu/2013/04/4-reasons-to-buy-oncosec-medical.html
3 fairly recent Biotech mergers
Amgen-BioVex $1B
$425MM in cash plus $575MM in payments for regulatory and sale milestones
1 drug in Phase 3 that was recruiting patients
1 drug under development in the UK
An operational manufacturing facility
Amgen-Micromet $1.16B in cash
1 drug under going multiple trials with no further progression than ongoing Phase 2s
Proprietary BiTE antibody technology for future research and potential milestone/royalty payments from licensing
Rights to one antibody in Phase 1
A site for R&D
Celgene-Avila $925MM
$350MM in cash plus $195MM for milestones of the drug's successful development and approval, plus $380MM for milestones from drugs developed and approved from the platform
1 drug in Phase 1
Proprietary Avilomics Platform for discovery and development
What does OncoSec have to offer:
NeoPulse:
Ready for market
CE Mark for Europe,
Patent for China for method of use and device.
ImmunoPulse:
Phase 2 Malignant Melanoma
Phase 2 Merkel Cell Carcinoma
Phase 2 Cutaneous T-cell Lymphoma
Producing outstanding data thus far, in fact leading the way with their results
Think for yourselves people and do not listen to those underselling this company. Just look at the facts. The potential ONCS has is phenomenal. Personally, I am holding onto every possible share I can acquire. Trading this stock is very risky as virtually every professional analyst has this stock with an undervalued rating right now. Many giving it a current value of $2.00-$2.50pps. With 10 upcoming catalysts and several upcoming events, ONCS is sitting on the platform ready to launch. When ONCS goes, it will GO!
SOURCE: http://finance.yahoo.com/mbview/threadview/;_ylt=Amv7TE0yjhxbEMRr2cAz9SveAohG;_ylu=X3oDMTB2Y252cDRkBHBvcwMxOQRzZWMDTWVkaWFNc2dCb2FyZHNYSFJVbHQ-;_ylg=X3oDMTBvaWppbXYzBGxhbmcDZW4tVVMEdGVzdANUZXN0X0FGQw--;_ylv=3?&bn=deaf8eed-7d4e-3e9e-8004-c66f510cb300&tid=1365384886725-a0390b7f-3634-4ffd-b530-522740419b25&tls=la%2Cd%2C0%2C3
3 fairly recent Biotech mergers
Amgen-BioVex $1B
$425MM in cash plus $575MM in payments for regulatory and sale milestones
1 drug in Phase 3 that was recruiting patients
1 drug under development in the UK
An operational manufacturing facility
Amgen-Micromet $1.16B in cash
1 drug under going multiple trials with no further progression than ongoing Phase 2s
Proprietary BiTE antibody technology for future research and potential milestone/royalty payments from licensing
Rights to one antibody in Phase 1
A site for R&D
Celgene-Avila $925MM
$350MM in cash plus $195MM for milestones of the drug's successful development and approval, plus $380MM for milestones from drugs developed and approved from the platform
1 drug in Phase 1
Proprietary Avilomics Platform for discovery and development
What does OncoSec have to offer:
NeoPulse:
Ready for market
CE Mark for Europe,
Patent for China for method of use and device.
ImmunoPulse:
Phase 2 Malignant Melanoma
Phase 2 Merkel Cell Carcinoma
Phase 2 Cutaneous T-cell Lymphoma
Producing outstanding data thus far, in fact leading the way with their results
Think for yourselves people and do not listen to those underselling this company. Just look at the facts. The potential ONCS has is phenomenal. Personally, I am holding onto every possible share I can acquire. Trading this stock is very risky as virtually every professional analyst has this stock with an undervalued rating right now. Many giving it a current value of $2.00-$2.50pps. With 10 upcoming catalysts and several upcoming events, ONCS is sitting on the platform ready to launch. When ONCS goes, it will GO!
SOURCE: http://finance.yahoo.com/mbview/threadview/;_ylt=Amv7TE0yjhxbEMRr2cAz9SveAohG;_ylu=X3oDMTB2Y252cDRkBHBvcwMxOQRzZWMDTWVkaWFNc2dCb2FyZHNYSFJVbHQ-;_ylg=X3oDMTBvaWppbXYzBGxhbmcDZW4tVVMEdGVzdANUZXN0X0FGQw--;_ylv=3?&bn=deaf8eed-7d4e-3e9e-8004-c66f510cb300&tid=1365384886725-a0390b7f-3634-4ffd-b530-522740419b25&tls=la%2Cd%2C0%2C3
Good luck to all
Pulse lines. The lines mark a rising pulse uptrend. The next third pulse will be much higher. Normally the third pulse is very strong.
ONCS last quarter report:
It is correct what the author says according to figures reported last financial quarter.
Cash= $8.98MM
Debt= $2.68MM
Net Income= ($1.61MM)
Source: http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=9164312-944-203016&type=sect&dcn=0001104659-13-021235
I like the author's conclusion.
OncoSec Medical is a tremendously undervalued company. It has a capitalization of $27MM and a cash flow of $9MM. Besides, it is carrying out several major studies. Immunopulse and Neopulse treatments can provide it with an income of $500MM annually minimum. This enterprise should have a minimum capitalization of $250MM or $2.5 per share.
*Pipeline overview data sourced from OncoSec Medical, all other data sourced from Nasdaq.com, CNN Money as well as the web of the previously mentioned company.
Source: http://www.bolsatrading.eu/2013/04/4-reasons-to-buy-oncosec-medical.html
Next range $0.02-$0.03 very easy.
Nice post. I like ILNS for medium term.
I recommend this reading about ONCS:
4 Reasons To Buy OncoSec Medical
Source: http://www.bolsatrading.eu/2013/04/4-reasons-to-buy-oncosec-medical.html
I recommend this reading about ONCS:
4 Reasons To Buy OncoSec Medical
Source: http://www.bolsatrading.eu/2013/04/4-reasons-to-buy-oncosec-medical.html
ONCS Weekly Chart
ONCS Weekly Chart
ONCS Professional Chart
ONCS Professional Chart
Thank you. I will apologize. I have explained my situation. ($5,000 in losses in NEOM)
I've deleted the comments you referenced. If you wanted you did, you could have asked otherwise. You should not ask with threats. I repeat that I have really lost in NEOM and I am not satisfied with the overall management YA global and Laura. I feel deceived by them. I think you should try that other investors do not fall prey to these people. IMO.
Thanks my friend. I like stock with Alzheimer treatments. My grandmother suffered this illness for a long time.
ONCS is a very undervalued company. They have three major phases II study. OncoSec Medical has a very small float 110MM shares only. This company can go before ASCO to $1 per share.
How much value a unique cancer treatment in the market and that has proven to work and can replace chemotherapy and surgery?
Market valuation of chemotherapy and surgery cancer: $47 Billion.
OncoSec Medical (ONCS) Targets $47 Billion Cancer Market :
http://www.marketwire.com/press-release/oncosec-medical-oncs-targets-47-billion-cancer-market-1627661.htm
ONCS may well become long term a $10 company or more.
ONCS has will soon become a big pharmaceutical. They have everything to get it.